# Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

> **NCT05465343** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College** · enrollment: 24 (actual)

## Conditions studied

- Furmonertinib
- EGFR-mutation
- NSCLC
- Brain Metastases

## Interventions

- **DRUG:** Furmonertinib 160 mg, Q.D.

## Key facts

- **NCT ID:** NCT05465343
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-11
- **Primary completion:** 2025-12-12
- **Final completion:** 2025-12-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465343, "Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05465343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*